203 related articles for article (PubMed ID: 32969762)
1. Liver enzyme
Lu JY; Tiwari AK; Freeman N; Zai GC; Luca V; Müller DJ; Tampakeras M; Herbert D; Emmerson H; Cheema SY; King N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Pharmacogenomics; 2020 Oct; 21(15):1065-1072. PubMed ID: 32969762
[No Abstract] [Full Text] [Related]
2. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.
Liou YJ; Wang YC; Bai YM; Lin CC; Yu SC; Liao DL; Lin MW; Chen JY; Lai IC
Neuropsychobiology; 2004; 49(4):167-73. PubMed ID: 15118351
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
Lanning RK; Zai CC; Müller DJ
Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
[TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
[TBL] [Abstract][Full Text] [Related]
7. Association study between the neurexin-1 gene and tardive dyskinesia.
Lanning R; Lett TA; Tiwari AK; Brandl EJ; de Luca V; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Remington G; Kennedy JL; Zai CC
Hum Psychopharmacol; 2017 Jan; 32(1):. PubMed ID: 28120489
[TBL] [Abstract][Full Text] [Related]
8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia.
Maes MS; Lu JY; Tiwari AK; Freeman N; de Luca V; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
Drug Dev Res; 2021 Aug; 82(5):678-684. PubMed ID: 32394511
[TBL] [Abstract][Full Text] [Related]
10. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.
Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Lerer B; Nimgaonkar VL; Thelma BK
Schizophr Res; 2005 Jun; 75(1):21-6. PubMed ID: 15820320
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.
Patsopoulos NA; Ntzani EE; Zintzaras E; Ioannidis JP
Pharmacogenet Genomics; 2005 Mar; 15(3):151-8. PubMed ID: 15861039
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
13. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
Ellingrod VL; Schultz SK; Arndt S
Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967
[TBL] [Abstract][Full Text] [Related]
14. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.
Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA
Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
16. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.
Andreassen OA; MacEwan T; Gulbrandsen AK; McCreadie RG; Steen VM
Psychopharmacology (Berl); 1997 May; 131(2):174-9. PubMed ID: 9201806
[TBL] [Abstract][Full Text] [Related]
17. Tardive dyskinesia: Who gets it and why.
Frei K
Parkinsonism Relat Disord; 2019 Feb; 59():151-154. PubMed ID: 30522959
[TBL] [Abstract][Full Text] [Related]
18. Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia.
Zai CC; Tiwari AK; Chowdhury NI; Yilmaz Z; de Luca V; Müller DJ; Potkin SG; Lieberman JA; Meltzer HY; Voineskos AN; Remington G; Kennedy JL
World J Biol Psychiatry; 2019 Jan; 20(1):91-95. PubMed ID: 28394697
[TBL] [Abstract][Full Text] [Related]
19. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
[TBL] [Abstract][Full Text] [Related]
20. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
